159 related articles for article (PubMed ID: 24583793)
1. Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor.
Kim TS; Cavnar MJ; Cohen NA; Sorenson EC; Greer JB; Seifert AM; Crawley MH; Green BL; Popow R; Pillarsetty N; Veach DR; Ku AT; Rossi F; Besmer P; Antonescu CR; Zeng S; Dematteo RP
Clin Cancer Res; 2014 May; 20(9):2350-62. PubMed ID: 24583793
[TBL] [Abstract][Full Text] [Related]
2. The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models.
Smyth T; Van Looy T; Curry JE; Rodriguez-Lopez AM; Wozniak A; Zhu M; Donsky R; Morgan JG; Mayeda M; Fletcher JA; Schöffski P; Lyons J; Thompson NT; Wallis NG
Mol Cancer Ther; 2012 Aug; 11(8):1799-808. PubMed ID: 22714264
[TBL] [Abstract][Full Text] [Related]
3. KIT
Banerjee S; Yoon H; Ting S; Tang CM; Yebra M; Wenzel AT; Yeerna H; Mesirov JP; Wechsler-Reya RJ; Tamayo P; Sicklick JK
Mol Cancer Ther; 2021 Oct; 20(10):2035-2048. PubMed ID: 34376580
[TBL] [Abstract][Full Text] [Related]
4. Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo.
Boichuk S; Galembikova A; Dunaev P; Micheeva E; Valeeva E; Novikova M; Khromova N; Kopnin P
Molecules; 2018 Oct; 23(10):. PubMed ID: 30326595
[TBL] [Abstract][Full Text] [Related]
5. DDR1/2 enhance KIT activation and imatinib resistance of primary and secondary KIT mutants in gastrointestinal stromal tumors.
Liu A; Zhang S; Wang M; Zhang L; Xu S; Nasimian A; Li S; Zhao S; Cao X; Tian J; Yu Y; Fan Z; Xiao K; Zhao H; Kazi JU; Ma L; Sun J
Mol Carcinog; 2024 Jan; 63(1):75-93. PubMed ID: 37737519
[TBL] [Abstract][Full Text] [Related]
6. TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours.
Saito Y; Takahashi T; Obata Y; Nishida T; Ohkubo S; Nakagawa F; Serada S; Fujimoto M; Ohkawara T; Nishigaki T; Sugase T; Koh M; Ishida T; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Nakajima K; Yamasaki M; Hirota S; Naka T; Mori M; Doki Y
Br J Cancer; 2020 Mar; 122(5):658-667. PubMed ID: 31857719
[TBL] [Abstract][Full Text] [Related]
7. Optimizing tyrosine kinase inhibitor therapy in gastrointestinal stromal tumors: exploring the benefits of continuous kinase suppression.
Le Cesne A; Blay JY; Reichardt P; Joensuu H
Oncologist; 2013; 18(11):1192-9. PubMed ID: 24136010
[TBL] [Abstract][Full Text] [Related]
8. KIT mutations and expression: current knowledge and new insights for overcoming IM resistance in GIST.
Zhou S; Abdihamid O; Tan F; Zhou H; Liu H; Li Z; Xiao S; Li B
Cell Commun Signal; 2024 Feb; 22(1):153. PubMed ID: 38414063
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine Kinase Inhibition Activates Intratumoral γδ T Cells in Gastrointestinal Stromal Tumor.
Etherington MS; Hanna AN; Medina BD; Liu M; Tieniber AD; Kwak HV; Tardy KJ; Levin L; Do KJ; Rossi F; Zeng S; DeMatteo RP
Cancer Immunol Res; 2024 Jan; 12(1):107-119. PubMed ID: 37922405
[TBL] [Abstract][Full Text] [Related]
10. Targeting BCL6 in Gastrointestinal Stromal Tumor Promotes p53-Mediated Apoptosis to Enhance the Antitumor Activity of Imatinib.
Zeng X; Zhao F; Jia J; Ma X; Jiang Q; Zhang R; Li C; Wang T; Liu W; Hao Y; Tao K; Lou Z; Zhang P
Cancer Res; 2023 Nov; 83(21):3624-3635. PubMed ID: 37556508
[TBL] [Abstract][Full Text] [Related]
11. Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea.
Kang YK; Kim KM; Sohn T; Choi D; Kang HJ; Ryu MH; Kim WH; Yang HK;
J Korean Med Sci; 2010 Nov; 25(11):1543-52. PubMed ID: 21060741
[TBL] [Abstract][Full Text] [Related]
12. 9.4 T static magnetic field ameliorates imatinib mesylate-induced toxicity and depression in mice.
Tian X; Wang C; Yu B; Fan Y; Zhang L; Zhang X
Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):314-327. PubMed ID: 36166081
[TBL] [Abstract][Full Text] [Related]
13. Cell-permeable PI3 kinase competitive peptide inhibits KIT mutant mediated tumorigenesis of gastrointestinal stromal tumor (GIST).
Jiang Z; Guo Y; Shi J; Zhang S; Zhang L; Wang Y; Li G; Bai R; Zhao H; Sun J
Mol Biol Rep; 2024 Jan; 51(1):98. PubMed ID: 38206538
[TBL] [Abstract][Full Text] [Related]
14. Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab.
D'Angelo SP; Shoushtari AN; Keohan ML; Dickson MA; Gounder MM; Chi P; Loo JK; Gaffney L; Schneider L; Patel Z; Erinjeri JP; Bluth MJ; Sjoberg A; Streicher H; Takebe N; Qin LX; Antonescu C; DeMatteo RP; Carvajal RD; Tap WD
Clin Cancer Res; 2017 Jun; 23(12):2972-2980. PubMed ID: 28007774
[No Abstract] [Full Text] [Related]
15. Inhibition of CSF1R and KIT With Pexidartinib Reduces Inflammatory Signaling and Cell Viability in Endometriosis.
Dunn TN; Cope DI; Tang S; Sirupangi T; Parks SE; Liao Z; Yuan F; Creighton CJ; Masand RP; Alpuing Radilla L; Guan X; Detti L; Monsivais D; Matzuk MM
Endocrinology; 2024 Feb; 165(4):. PubMed ID: 38227801
[TBL] [Abstract][Full Text] [Related]
16. Golgi retention and oncogenic KIT signaling via PLCγ2-PKD2-PI4KIIIβ activation in gastrointestinal stromal tumor cells.
Obata Y; Kurokawa K; Tojima T; Natsume M; Shiina I; Takahashi T; Abe R; Nakano A; Nishida T
Cell Rep; 2023 Sep; 42(9):113035. PubMed ID: 37616163
[TBL] [Abstract][Full Text] [Related]
17. RAF1 facilitates KIT signaling and serves as a potential treatment target for gastrointestinal stromal tumor.
Zhang L; Zhang S; Cao X; Shi J; Zhao S; Tian J; Xiao K; Wang M; Liu J; Wang C; Zhou L; Yu Y; Zhao H; Li S; Sun J
Oncogene; 2024 May; ():. PubMed ID: 38760447
[TBL] [Abstract][Full Text] [Related]
18. Targeting cells of the myeloid lineage attenuates pain and disease progression in a prostate model of bone cancer.
Thompson ML; Jimenez-Andrade JM; Chartier S; Tsai J; Burton EA; Habets G; Lin PS; West BL; Mantyh PW
Pain; 2015 Sep; 156(9):1692-1702. PubMed ID: 25993548
[TBL] [Abstract][Full Text] [Related]
19. Discovery and optimization of natural-based nanomolar c-Kit inhibitors via in silico and in vitro studies.
Nada H; Kim S; Godesi S; Lee J; Lee K
J Biomol Struct Dyn; 2023; 41(21):11904-11915. PubMed ID: 36636795
[TBL] [Abstract][Full Text] [Related]
20. Tumor-targeting
Miyake K; Kawaguchi K; Miyake M; Zhao M; Kiyuna T; Igarashi K; Zhang Z; Murakami T; Li Y; Nelson SD; Bouvet M; Elliott I; Russell TA; Singh AS; Hiroshima Y; Momiyama M; Matsuyama R; Chishima T; Singh SR; Endo I; Eilber FC; Hoffman RM
Heliyon; 2018 Jun; 4(6):e00643. PubMed ID: 30003151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
